Manganese improves anti-PD-L1 immunotherapy via eliciting type I interferon signaling in melanoma [0.03%]
锰通过诱导黑色素瘤中I型干扰素信号传导来改善抗PD-L1免疫疗法
Xiaoxin Zhang,Jianhua Deng,Renjie Wu et al.
Xiaoxin Zhang et al.
The immune checkpoint inhibitor therapy represented by blocking programmed cell death protein 1/ programmed cell death-ligand 1 (PD-1/PD-L1) has made significant progress in melanoma treatment. However, the response rate and therapeutic eff...
Phase II trial of multi-tyrosine kinase inhibitor ESK981 in combination with PD-1 inhibitor nivolumab in patients with metastatic castration-resistant prostate cancer [0.03%]
ESK981联合PD-1抑制剂纳武利尤单抗治疗转移性去势抵抗性前列腺癌的II期临床试验
Elisabeth I Heath,Wei Chen,Jae E Choi et al.
Elisabeth I Heath et al.
Increasing the response rates of immune checkpoint inhibitors in patients with metastatic castration-resistant prostate cancer (mCRPC) presents a significant challenge. ESK981 is a multi-tyrosine kinase and PIKfyve lipid kinase inhibitor th...
Modernizing the assessment and reporting of adverse events in oncology clinical trials using complementary statistical approaches: a case study of the MOTIVATE trial [0.03%]
使用互补统计方法 modernize 肿瘤临床试验中不良事件的评估和报告：来自 MOTIVATE 试验的一个案例研究
Mathilde Morisseau,Carlos Gomez-Roca,Marie Viala et al.
Mathilde Morisseau et al.
The reporting of adverse events (AEs) is fundamental to characterize safety profiles of novel therapeutic drug classes, however, conventional analysis strategies are suboptimal tools for this task. We therefore attempted to contribute to th...
A phase II study of ME2136 (Asenapine Maleate) plus standard antiemetic therapy for patients, including diabetic patients, receiving cisplatin-based chemotherapy [0.03%]
评价阿senapine马来酸盐(Me2136)片联合标准止吐方案治疗以顺铂为基础化疗患者(包括糖尿病患者)疗效和安全性的II期临床试验
Satoshi Hamauchi,Hirofumi Yasui,Tomoya Yokota et al.
Satoshi Hamauchi et al.
Olanzapine combined with the neurokinin-1 receptor antagonist, palonosetron and dexamethasone is the standard treatment for chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). However, the use of ola...
Anti-ovarian cancer migration and toxicity characteristics of a platinum(IV) pro-drug with axial HDAC inhibitor ligands in zebrafish models [0.03%]
含轴向组蛋白去乙酰化酶抑制剂配体的铂(IV)前药在斑马鱼模型中的抗卵巢癌迁移和毒性特征
Salma Begum,Scheldon D Irvin,Carol K Cox et al.
Salma Begum et al.
Ovarian cancer is the fifth leading cause of cancer related death in the United States. Cisplatin is a platinum-based anti-cancer drug used against ovarian cancer that enters malignant cells and then damages DNA causing cell death. Typicall...
Unraveling the potential biomarkers of immune checkpoint inhibitors in advanced ovarian cancer: a comprehensive review [0.03%]
免疫检查点抑制剂治疗卵巢癌的生物标志物研究进展：全面综述
Jian-Rong Na,Yaqin Liu,Kun Fang et al.
Jian-Rong Na et al.
The ongoing research on the role of immunotherapy in advanced ovarian cancer (OC) and current clinical trials indicate that patients shown limited response to immune checkpoint inhibitor (ICI) monotherapy. When combined with other treatment...
Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients [0.03%]
关于维奈克拉联合卡非佐米和地塞米松治疗复发/难治t(11;14)多发性骨髓瘤患者的暴露反应关系研究
Mohamed Ali Badawi,Benjamin Engelhardt,Edyta Dobkowska et al.
Mohamed Ali Badawi et al.
Venetoclax is a first in class BCL-2 inhibitor, currently under investigation for the treatment of t(11;14) multiple myeloma (MM). The objective of this analysis was to characterize the exposure-efficacy and exposure-safety relationships of...
Predictive value of ZFHX4 mutation for the efficacy of immune checkpoint inhibitors in non-small cell lung cancer and melanoma [0.03%]
ZFHX4突变对非小细胞肺癌和黑色素瘤免疫检查点抑制剂疗效的预测价值
Cong Fu,Haoran Gu,Lin Sun et al.
Cong Fu et al.
Studies have shown that the Zinc finger homeobox 4 (ZFHX4) might be a factor in the prognosis of malignancies. However, little is known about the association between the ZFHX4 mutation and the effectiveness of immune checkpoint inhibitors (...
Clinical research progress of fruquintinib in the treatment of malignant tumors [0.03%]
呋喹替尼治疗恶性肿瘤的临床研究进展
Shihao Zhao,Wenhui Wang,Jingyi Li et al.
Shihao Zhao et al.
Malignant tumors represent an important cause of mortality within the global population. Tumor angiogenesis, recognized as one of the key hallmarks of malignant tumors, is crucial for supplying essential nutrients and oxygen for tumor growt...
Gremlin1: a BMP antagonist with therapeutic potential in Oncology [0.03%]
Gremlin1：一种有望运用于肿瘤学治疗的BMP抑制剂
Zhao Jin,Yanshuo Cao
Zhao Jin
Gremlins, originating from early 20th-century Western folklore, are mythical creatures known for causing mechanical malfunctions and electronic failures, aptly dubbed "little devils". Analogously, GREM1 acts like a horde of these mischievou...